Seeking Alpha

GTX (GTXI -12.7%) drops on a negative article from The Street's Adam Feuerstein, saying that...

GTX (GTXI -12.7%) drops on a negative article from The Street's Adam Feuerstein, saying that Phase 3 studies of Enobosarm, its cancer-related muscle wasting drug, will fail. Feuerstein says that prior data shows that the treatment may be struggling to demonstrate both an increase muscle mass and improve muscle performance or function- which the FDA requires for approval.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)